- Home
- BFRI
BFRI
Biofrontera Inc.
as 06-26-2025 4:00pm EST
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 7.5M | IPO Year: | 2021 |
| Target Price: | $2.75 | AVG Volume (30 days): | 188.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.22 | Next Earning Date: | 08-13-2025 |
| Revenue: | $37,997,000 | Revenue Growth: | 14.28% |
| Revenue Growth (this year): | 11.75% | Revenue Growth (next year): | 17.09% |
Latest Biofrontera Inc. News
BFRI Breaking Stock News: Dive into BFRI Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
Biofrontera Inc. Confirms Talks on Merger, Licensing Changes with Biofrontera AG
GlobeNewswire
17 days ago
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
GlobeNewswire
25 days ago
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
GuruFocus.com
a month ago
Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Thomson Reuters StreetEvents
a month ago
Q1 2025 Biofrontera Inc Earnings Call
GlobeNewswire
a month ago
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
a month ago
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
ACCESS Newswire
2 months ago
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Compare BFRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BFRI Biofrontera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.